Skip to main content
main-content
Top

13-06-2017 | Atezolizumab | Article

Phase II Trial of Atezolizumab As First-Line or Subsequent Therapy for Patients With Programmed Death-Ligand 1–Selected Advanced Non–Small-Cell Lung Cancer (BIRCH)

Peters S et al. J Clin Oncol 2017; 35(24): 781-2789. doi: 10.1200/JCO.2016.71.9476

Please log in to get access to this content

Related topics